P1.03-10 the Molecular Spectrum of NF1 Variants in Chinese Non-Small-Cell Lung Cancer Patients
Q. Zhang,C. Xu,W. Wang,W. Zhuang,Y. Zhu,Z. Huang,Y. Chen,G. Chen,M. Fang,T. Lv,Y. Song
DOI: https://doi.org/10.1016/j.jtho.2018.08.691
IF: 20.121
2018-01-01
Journal of Thoracic Oncology
Abstract:Activation of the RAS/MAPK pathway is critical in non-small-cell lung cancer. Non-small-cell lung cancer can be grouped into four molecular subtypes based on their main genetic driver: EGFR-mutant, ALK-fusion, ROS1-fusion, and triple wild-type tumors. The NF1 protein, neurofibromin 1, negatively regulates RAS proteins through GTPase activity. Somatic mutations in NF1 cause neurofibromatosis type I, a common genetic tumor syndrome caused by dysregulation of the RAS/MAPK pathway, ie, RAS pathy. While the genetic sites of NF1 mutation NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring NF1 mutations. A total of 337 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of NF1 mutation and other genes were detected by next generation sequencing. NF1 gene mutation rate was 6.23% (21/337) in non-small cell lung cancer, including M645V (3 patients), A1998V (1 patient), Q83E (1 patient), P654T (1 patient), Q912* (1 patient), C324* (1 patient), C1032S (1 patient), I1628M (1 patient), L43V (1 patient), A861Qfs*17 (1 patient), Q239E (1 patient), D1623N (1 patient), T586Vfs*18 (1 patient), R2328C (1 patient), E41* (1 patient), V437Nfs*35 (1 patient), P2046L plus G1219* (1 patient), D2055Mfs*6 plus T2133Sfs*45 (1 patient) and C1288F plus K2252* (1 patient), and median overall survival (OS) for these patients was 10.0 months. Among them, all patients were NF1 gene with co-occurring mutation. Briefly, patients with (n=3) or without (n=18) co-occurring EGFR mutations had a median OS of 15.5 months and 10.0 months respectively (P=0.69); patients with (n=18) or without (n=3) co-occurring TP53 mutations had a median OS of 10.0 months and 6.0 months respectively (P=0.21); patients with (n=3) or without (n=18) co-occurring RB1 mutations had a median OS of 19.5 months and 9.0 months respectively (P=0.27); patients with (n=3) or without (n=18) co-occurring SMARCA4 mutations had a median OS of 20.5 months and 9.0 months respectively (P=0.19). Patients with complex mutations benefited more from therapy than those with single mutations. NF1 genetic alter occurs in a subset of NSCLC, and improved understanding of the implications of NF1 aberrations is critical for the identification of therapeutic target candidates.